GIM-407
Autoimmune Disease
PreclinicalActive
Key Facts
About Georgiamune
Georgiamune is a private, preclinical-stage biotech leveraging a proprietary target discovery platform to develop novel immunomodulators. The company's strategy centers on rebalancing the immune system with first-in-class assets, including a dual-functioning antibody for cancer and small molecules that either inhibit or activate regulatory T cells (Tregs) for cancer and autoimmune diseases, respectively. Headquartered in Gaithersburg, MD, Georgiamune is building a portfolio aimed at large indications with high unmet need. It operates as a pre-revenue company with a team experienced in biopharma R&D.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Fusion Immunotherapeutic | HCW Biologics | Clinical Trial |
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Not Specified (Autoimmune Focus) | Narwhal Bio | Pre-clinical |
| Undisclosed Precision Biologic | Rhapsogen | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| Autoimmunity Program | Accipiter Biosciences | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Appus | BioVectis | Pre-clinical |
| Leap 1121 | Ability Biotherapeutics | Preclinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |